2026年上半年，先瑞达医疗-B实现营业收入3.32亿元，同比下降5.6%；经调整净利润0.91亿元，同比下降9.0%。同期毛利率为70.3%，较上年同期的74.2%减少3.9个百分点。
在成本结构方面，销售成本0.98亿元，同比上升8.5%，主要由于部分产品带量采购价格下降及市场竞争加剧背景下的销售结构变化。销售及分销费用0.41亿元，同比下降26.8%，约占总收入的12.3%。行政开支0.32亿元，同比下降14.0%。研发投入2.39亿元，同比大幅增长133.8%，约占总营收的72.2%。研发成本显著增长，主要系终止一项产品在美国的临床试验，致使一次性减值损失及相关费用拨备合计约1.51亿元。
业务方面，动脉介入产品实现收入1.41亿元，同比下降32.4%，主因是公司部分动脉介入产品在第六批国家集采中以较低价格中标；而静脉介入、血管通路及其他产品的收入达到1.91亿元，同比增长36.0%，主要来自于临床应用扩充及海外市场的持续拓展。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.